Shun Li from Lakeland, FL, age 32

Professional Records

License Records

Shun Z Li

Address:

189 02 64 Ave, Fresh Meadows, NY

Phone:

(718) 791-5965

License #:

57808 - Active

Category:

Health Care

Issued Date:

Dec 14, 2009

Effective Date:

Dec 14, 2009

Expiration Date:

Aug 31, 2017

Type:

Massage Therapist

Resumes

Project Engineer

View page

Location:

3012 Blackberry Ave, San Ramon, CA 94582

Industry:

Construction

Work:

Turner Construction Company
Project Engineer
Yates Construction
Project Engineer and Consultant
University of Florida Jan 2013 - May 2014
Research Assistant
University of Florida Jan 2013 - May 2013
Teaching Assistant

Education:

University of Florida 2012 - 2013
Master of Science, Masters, Chemical Engineering University of Rochester 2007 - 2011
Bachelors, Bachelor of Science, Chemical Engineering Brighton High School 2007

Skills:

Project Management
Cost Control
Cpm Scheduling
Project Closeout
Building Information Modeling
Lean Construction
Construction Management
Semiconductor Fabrication
Device Characterization
Unit Operations
Matlab
Research
Chemical Engineering
Materials Science

Languages:

English
Mandarin

Certifications:

Cm-Bim, Cm-Lean
Cm-Bim
Cm-Lean
Pmp

Shun Li

View page

Shun Li

View page

Shun Li

View page

Business Records

Name / Title

Company / Classification

Phones & Addresses

Shun Li
Owner

Shun Li Chinese Restaurant
Eating Places

1523 Pitkin Ave, Brooklyn, NY 11212

Shun Ai Li

HPA GLOBAL TRADING INC

Shun Ai Li 3153 Fulton St, Brooklyn, NY 11208
3153 Bulton St, Brooklyn, NY 11229
3153 Fulton St, Brooklyn, NY 11208

Publications

Us Patents

Methods And Compositions For Targeting Tgf-Ss Signaling In Cd4+ Helper T Cells For Cancer Immunotherapy

View page

US Patent:

20220267442, Aug 25, 2022

Filed:

Jul 17, 2020

Appl. No.:

17/626941

Inventors:

- New York NY, US
Shun Li - New York NY, US
Ming Liu - New York NY, US

International Classification:

C07K 16/28
C07K 14/71
A61P 35/00
A61K 45/06
A61K 38/17
A61K 39/395
C07K 16/24

Abstract:

The present disclosure provides fusion proteins that specifically inhibit transforming growth factor-β (TGF-β) signaling in CD4+ helper T cells, and engineered CD4+ helper T cells that are deficient in TGF-β signaling, to counteract tumor-induced immune tolerance and promote anti-tumor immunity. The fusion proteins and engineered CD4+ helper T cells of the present technology are useful in methods for treating cancer, and enhancing the efficacy of other therapeutic agents against refractory cancer cells.

Videos & Images